Showing results (171-180 of 366) with videos related to
Sort By:
Pageof 37
Nature Communications|June 24, 2020
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumoursJoão M Fernandes Neto, Ernest Nadal, Evert Bosdriesz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJulien Mazières, Solange Peters, Benoit Lepage, et al.Lung Cancer (Amsterdam, Netherlands)|March 8, 2022
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, et al.European Journal of Cancer (Oxford, England : 1990)|March 16, 2013
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumoursJean-Charles Soria, José Baselga, Nasser Hanna, et al.Thorax|November 26, 2018
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM stagingElena Martínez-Terroba, Carmen Behrens, Jackeline Agorreta, et al.JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.Clinical Pharmacokinetics|December 11, 2023
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung CancerJoseph Chen, Alessandra Bearz, Dong-Wan Kim, et al.The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLCJacek Jassem, Filippo de Marinis, Giuseppe Giaccone, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2017
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung CancerEnriqueta Felip, Fabrice Barlesi, Benjamin Besse, et al.Pageof 37